WO2003046176A3 - Protein-protein interactions in human immunodeficiency virus - Google Patents

Protein-protein interactions in human immunodeficiency virus Download PDF

Info

Publication number
WO2003046176A3
WO2003046176A3 PCT/EP2002/013868 EP0213868W WO03046176A3 WO 2003046176 A3 WO2003046176 A3 WO 2003046176A3 EP 0213868 W EP0213868 W EP 0213868W WO 03046176 A3 WO03046176 A3 WO 03046176A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
protein interactions
immunodeficiency virus
human immunodeficiency
polypeptides
Prior art date
Application number
PCT/EP2002/013868
Other languages
French (fr)
Other versions
WO2003046176A2 (en
Inventor
Pierre Legrain
Jean-Christophe Rain
Richard Benarous
Stephane Emiliani
Clarisse Berlioz-Torrent
Guillaume Blot
Original Assignee
Hybrigenics Sa
Pierre Legrain
Jean-Christophe Rain
Richard Benarous
Stephane Emiliani
Clarisse Berlioz-Torrent
Guillaume Blot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybrigenics Sa, Pierre Legrain, Jean-Christophe Rain, Richard Benarous, Stephane Emiliani, Clarisse Berlioz-Torrent, Guillaume Blot filed Critical Hybrigenics Sa
Priority to CA2468326A priority Critical patent/CA2468326C/en
Priority to EP02792922A priority patent/EP1451214A2/en
Priority to AU2002358631A priority patent/AU2002358631A1/en
Publication of WO2003046176A2 publication Critical patent/WO2003046176A2/en
Publication of WO2003046176A3 publication Critical patent/WO2003046176A3/en
Priority to US10/853,807 priority patent/US7763254B2/en
Priority to US12/072,390 priority patent/US8197821B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to protein-protein interactions involved in AIDS. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, antibodies to the complexes, selected Interacting Domains (SID®) which are identified due to the protein-protein interactions, methods for screening drugs of agents which modulate the interaction of proteins and pharmaceutical compositions that are capable of modulating the protein-protein interactions.
PCT/EP2002/013868 2001-11-26 2002-11-26 Protein-protein interactions in human immunodeficiency virus WO2003046176A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2468326A CA2468326C (en) 2001-11-26 2002-11-26 Protein-protein interactions in human immunodeficiency virus
EP02792922A EP1451214A2 (en) 2001-11-26 2002-11-26 Protein-protein interactions in human immunodeficiency virus
AU2002358631A AU2002358631A1 (en) 2001-11-26 2002-11-26 Protein-protein interactions in human immunodeficiency virus
US10/853,807 US7763254B2 (en) 2001-11-26 2004-05-26 Human immunodeficiency virus integrase-LEDGF p75 isoform protein-protein interactions
US12/072,390 US8197821B2 (en) 2001-11-26 2008-02-25 Human immunodeficiency virus integrase—Transportin—SR protein—protein interactions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33334601P 2001-11-26 2001-11-26
US60/333,346 2001-11-26
US38513202P 2002-05-31 2002-05-31
US60/385,132 2002-05-31

Related Child Applications (3)

Application Number Title Priority Date Filing Date
EP09178541.0A Previously-Filed-Application EP2186820B1 (en) 2001-11-26 2002-11-26 Protein-protein interactions in human immunodeficiency virus
EP08006236.7A Previously-Filed-Application EP2014674B1 (en) 2001-11-26 2002-11-26 Protein-protein interactions in human immunodeficiency virus
US10/853,807 Continuation US7763254B2 (en) 2001-11-26 2004-05-26 Human immunodeficiency virus integrase-LEDGF p75 isoform protein-protein interactions

Publications (2)

Publication Number Publication Date
WO2003046176A2 WO2003046176A2 (en) 2003-06-05
WO2003046176A3 true WO2003046176A3 (en) 2003-11-27

Family

ID=26988677

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/013868 WO2003046176A2 (en) 2001-11-26 2002-11-26 Protein-protein interactions in human immunodeficiency virus

Country Status (6)

Country Link
US (2) US7763254B2 (en)
EP (3) EP2014674B1 (en)
AU (1) AU2002358631A1 (en)
CA (1) CA2468326C (en)
ES (2) ES2462740T3 (en)
WO (1) WO2003046176A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003017943A2 (en) 2001-08-22 2003-03-06 Myriad Genetics, Inc Therapeutic compositions and methods for treating viral infection
EP2371955A1 (en) * 2002-09-26 2011-10-05 K.U. Leuven Research & Development Integrase cofactor
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
PT2284266E (en) 2002-11-14 2013-12-17 Thermo Fisher Scient Biosciences Inc Sirna targeting tp53
BRPI0504117A (en) * 2005-09-05 2007-05-22 Fundacao De Amparo A Pesquisa epitopes, combination of epitopes, uses of epitopes or their combination, composition, uses of composition, anti-HIV-1 prophylactic vaccines, therapeutic vaccines, method for identifying epitopes and methods for treatment or prevention.
GB0801940D0 (en) * 2008-02-01 2008-03-12 Univ Leuven Kath Inhibitors of lentiviral replication
EP2196453A1 (en) 2008-12-10 2010-06-16 Cellvir Novel substituted aryl derivatives, their process of preparation and their therapeutical uses as anti-HIV agents
WO2012112884A2 (en) * 2011-02-17 2012-08-23 THE GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL & PREVENTION Real-time pcr point mutation assays for detecting hiv - 1 resistance to antiviral drugs
CN103540644B (en) * 2012-07-10 2015-04-01 中国医学科学院病原生物学研究所 Method for screening anti-HIV-1 (human immunodeficiency virus-1) medicament
JP6847852B2 (en) * 2015-04-17 2021-03-31 ジェニスフィア・エルエルシー SiRNA inhibition of human antigen R expression for cancer treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066722A1 (en) * 1999-04-30 2000-11-09 Hybrigenics S.A. Collection of prokaryotic dna for two hybrid systems helicobacter pylori protein-protein interactions and application thereof
US6222024B1 (en) * 1994-05-24 2001-04-24 The Trustees Of Columbia University In The City Of New York Nucleic acids encoding a human immunodeficiency virus type 1 (HIV-1) integrase interactor protein (INI-1)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
CA2092323A1 (en) 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
WO1993014188A1 (en) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
AU3940293A (en) 1992-04-03 1993-11-08 Alexander T. YOUNG Gene therapy using targeted viral vectors
US6309821B1 (en) * 1996-05-16 2001-10-30 Incyte Genomics, Inc. DNA encoding a PAC10 human homolog
US6083762A (en) 1996-05-31 2000-07-04 Packard Instruments Company Microvolume liquid handling system
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6333154B1 (en) 1997-12-04 2001-12-25 Institut Pasteur Bacterial multi-hybrid system and applications thereof
US6187535B1 (en) 1998-02-18 2001-02-13 Institut Pasteur Fast and exhaustive method for selecting a prey polypeptide interacting with a bait polypeptide of interest: application to the construction of maps of interactors polypeptides
AU5143099A (en) 1998-07-30 2000-02-21 Universite De Montreal Protein fragment complementation assays for the detection of biological or drug interactions
EP1140973A4 (en) 1998-12-22 2002-10-30 Myriad Genetics Inc Protein-protein interactions in neurodegenerative disorders
WO2000058473A2 (en) * 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
WO2001024810A1 (en) * 1999-10-05 2001-04-12 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2003087299A2 (en) * 2002-04-05 2003-10-23 Sunesis Pharmaceuticals, Inc. Methods of characterizing molecular interaction sites on proteins
GB2393440A (en) 2002-09-26 2004-03-31 Leuven K U Res & Dev Inhibition of retroviral integrase
EP2371955A1 (en) 2002-09-26 2011-10-05 K.U. Leuven Research & Development Integrase cofactor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6222024B1 (en) * 1994-05-24 2001-04-24 The Trustees Of Columbia University In The City Of New York Nucleic acids encoding a human immunodeficiency virus type 1 (HIV-1) integrase interactor protein (INI-1)
WO2000066722A1 (en) * 1999-04-30 2000-11-09 Hybrigenics S.A. Collection of prokaryotic dna for two hybrid systems helicobacter pylori protein-protein interactions and application thereof

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BENICHOU S ET AL: "Use of the two-hybrid system to identify cellular partners of the HIV1 Nef protein.", RESEARCH IN VIROLOGY, vol. 148, no. 1, 1997, pages 71 - 73, XP002247153, ISSN: 0923-2516 *
DE SOULTRAIT VAEA RICHARD ET AL: "A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.", JOURNAL OF MOLECULAR BIOLOGY, vol. 318, no. 1, 2002, 19 April, 2002, pages 45 - 58, XP002247154, ISSN: 0022-2836 *
FIELDS S ET AL: "THE TWO-HYBRID SYSTEM: AN ASSAY FOR PROTEIN-PROTEIN INTERACTIONS", TRENDS IN GENETICS, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 10, no. 8, 1 August 1994 (1994-08-01), pages 286 - 292, XP000647708, ISSN: 0168-9525 *
GARRUS JENNIFER E ET AL: "Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding.", CELL, vol. 107, no. 1, 5 October 2001 (2001-10-05), pages 55 - 65, XP002247151, ISSN: 0092-8674 *
HOLLOWAY A F ET AL: "Functional interaction between the HIV transactivator Tat and the transcriptional coactivator PC4 in T cells.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 14 JUL 2000, vol. 275, no. 28, 14 July 2000 (2000-07-14), pages 21668 - 21677, XP002247152, ISSN: 0021-9258 *
LEGRAIN P ET AL: "Genome-wide protein interaction maps using two-hybrid systems", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 480, no. 1, 25 August 2000 (2000-08-25), pages 32 - 36, XP004337490, ISSN: 0014-5793 *
LEGRAIN P ET AL: "Protein-protein interaction maps: a lead towards cellular functions", TRENDS IN GENETICS, ELSEVIER, AMSTERDAM, NL, vol. 17, no. 6, 1 June 2001 (2001-06-01), pages 346 - 352, XP004249491, ISSN: 0168-9525 *
See also references of EP1451214A2 *
STARK LESLEY A ET AL: "Human immunodeficiency virus type 1 (HIV-1) viral protein R (Vpr) interacts with Lys-tRNA synthetase: Implications for priming of HIV-1 reverse transcription", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 72, no. 4, April 1998 (1998-04-01), pages 3037 - 3044, XP002209972, ISSN: 0022-538X *
TSUCHIYA H ET AL: "IDENTIFICATION OF A NOVEL PROTEIN (VBP-1) BINDING TO THE VON HIPPEL-LINDAU (VHL) TUMOR SUPPRESSOR GENE PRODUCT", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 56, no. 13, 1 July 1996 (1996-07-01), pages 2881 - 2885, XP002039978, ISSN: 0008-5472 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality

Also Published As

Publication number Publication date
EP1451214A2 (en) 2004-09-01
CA2468326C (en) 2015-11-17
EP2014674A1 (en) 2009-01-14
US20060034860A1 (en) 2006-02-16
EP2014674B1 (en) 2014-02-12
EP2186820B1 (en) 2016-06-08
AU2002358631A8 (en) 2003-06-10
US7763254B2 (en) 2010-07-27
CA2468326A1 (en) 2003-06-05
US8197821B2 (en) 2012-06-12
WO2003046176A2 (en) 2003-06-05
EP2186820A1 (en) 2010-05-19
AU2002358631A1 (en) 2003-06-10
ES2605445T3 (en) 2017-03-14
US20090004719A1 (en) 2009-01-01
ES2462740T3 (en) 2014-05-26

Similar Documents

Publication Publication Date Title
WO2002057303A3 (en) Protein-protein interactions between shigella flexneri polypeptides and mammalian polypeptides
WO2003046176A3 (en) Protein-protein interactions in human immunodeficiency virus
WO2002086122A3 (en) Protein-protein interactions in adipocytes
EP1218368A4 (en) COMPOSITIONS AND METHODS FOR MODULATING APOPTOSIS IN CELLS OVER-EXPRESSING bcl-2 FAMILY MEMBER PROTEINS
AU2002305450A1 (en) Proteomimetic compounds and methods
WO2005095457A3 (en) Immunoglobulins
WO2003057134A3 (en) Specific binding agents of human angiopoietin-2
WO2002024909A3 (en) Receptor nucleic acids and polypeptides
WO2002065134A3 (en) Modulators of p53-p300 interactions and screening methods therefor
UA87106C2 (en) Nogo receptor binding protein
WO2007098198A3 (en) Modulation of bone formation
HUP0402496A2 (en) Growth hormone fusion protein
WO2002053726A3 (en) Protein-protein interactions in adipocyte cells
WO1995011975A3 (en) Retroviral superantigens, superantigen peptides, and methods of use
AU2002237195A1 (en) Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus
WO2002090544A3 (en) Protein-protein interactions in adipocyte cells (3)
WO2002092765A3 (en) Novel telomerase inhibitors and uses therefor
UA72875C2 (en) Novel proteins which bind human <sub>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-amyloid peptide, polynucleotides which encode theM
WO2004066933A3 (en) Compositions and methods for treating cancer using igsf9 and liv-1
WO2002066501A3 (en) PROTEIN-PROTEIN INTERACTIONS IN $i(HELICOBACTER PYLORI)
WO2003045990A3 (en) Protein-protein interactions involving transforming growth factor beta signalling
WO2002050261A3 (en) PROTEINS THAT INTERACT WITH βTRCP
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
MXPA04002103A (en) A caspase- 8 binding protein, its preparation and use.
WO2003075014A3 (en) Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002792922

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10853807

Country of ref document: US

Ref document number: 2468326

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002792922

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10853807

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP